CONJUPRI
Clinical safety rating: caution
Comprehensive clinical and safety monograph for CONJUPRI (CONJUPRI).
Selective vasopressin V1a receptor antagonist, inhibiting vasopressin-mediated smooth muscle contraction in arterioles, leading to vasodilation and reduced portal pressure.
| Metabolism | Primarily hepatic via CYP3A4 and CYP2C19; minor renal excretion. |
| Excretion | Primarily hepatic metabolism via CYP3A4, with 80-90% excreted as metabolites in feces (biliary) and 10-20% in urine as unchanged drug or metabolites. |
| Half-life | Terminal elimination half-life is approximately 9-16 hours (mean 12 hours) in healthy volunteers, supporting once-daily dosing. Half-life may be prolonged in patients with mild-to-moderate hepatic impairment. |
| Protein binding | Approximately 99% bound to plasma proteins, primarily albumin and alpha-1-acid glycoprotein. |
| Volume of Distribution | Volume of distribution is approximately 50 L (0.7-1.0 L/kg), indicating extensive extravascular distribution. High Vd suggests significant tissue binding. |
| Bioavailability | Absolute bioavailability is approximately 30% (range 20-40%) due to extensive first-pass metabolism. Food does not significantly affect bioavailability. |
| Onset of Action | Oral administration: Onset of antihypertensive effect occurs within 2-4 hours post-dose, with peak effect typically observed at 6-12 hours. |
| Duration of Action | Duration of antihypertensive effect is approximately 24 hours, allowing for once-daily dosing. Clinical trials demonstrated sustained blood pressure reduction over the dosing interval. |
| Molecular Weight | 449.5 |
Adults: Initial 10 mg orally once daily, titrate to 20-40 mg once daily. Maximum 40 mg/day.
| Dosage form | TABLET |
| Renal impairment | eGFR 30-60 mL/min: No adjustment; eGFR <30 mL/min: Not recommended (insufficient data). |
| Liver impairment | Child-Pugh A (mild): No adjustment; Child-Pugh B or C: Contraindicated. |
| Pediatric use | Safety and efficacy not established in pediatric patients. |
| Geriatric use | Start at lower end of dosing range (10 mg daily) due to increased sensitivity; monitor renal function. |
| 1st trimester | Avoid use due to potential teratogenicity based on animal reproductive studies. |
| 2nd trimester | Not recommended; may cause fetal renal impairment and oligohydramnios. |
| 3rd trimester | Contraindicated; risk of neonatal renal failure, pulmonary hypoplasia, and death. |
Clinical note
Comprehensive clinical and safety monograph for CONJUPRI (CONJUPRI).
| Placental transfer | Significant transfer; crosses placenta in animal models; human data limited but expected due to low molecular weight. |
| Breastfeeding | No data on excretion in human milk; due to potential for serious adverse reactions, advise against breastfeeding during therapy and for 3 weeks after last dose. |
| Lactation Rating |
■ FDA Black Box Warning
WARNING: RISK OF SERIOUS HYPOTENSION AND HYPOVOLEMIA. Monitor hemodynamics closely; discontinue or adjust dose if hypotension occurs.
| Serious Effects |
PregnancyHypersensitivity to Conjupri or any componentHistory of angioedema with prior ACE inhibitor therapyConcurrent use with aliskiren in diabetic patients
| Precautions | Hypotension/Hypovolemia, Cardiac ischemia, Electrolyte imbalances (hyperkalemia, hyponatremia), Hepatic encephalopathy, Monitor renal function and blood pressure |
| Food/Dietary | Avoid grapefruit and grapefruit juice due to CYP3A4 inhibition. Take with food to reduce GI upset. Avoid alcohol as it may increase hepatotoxicity risk. |
Loading safety data…
| L5 - Contraindicated |
| Teratogenic Risk | Conjupri (levamlodipine) is an S-enantiomer of amlodipine. Limited human data; animal studies show no teratogenicity at clinically relevant doses. However, calcium channel blockers may cause fetal hypoxia, IUGR, and preterm delivery due to maternal hypotension. Risk in first trimester is low; second/third trimester: potential fetal risks include reduced uteroplacental perfusion, fetal distress, and neonatal hypotension. Use only if maternal benefit outweighs fetal risk. |
| Fetal Monitoring | Monitor maternal blood pressure and heart rate regularly. Assess fetal growth and amniotic fluid volume via ultrasound in third trimester. Monitor for signs of uteroplacental insufficiency. Neonatal monitoring for hypotension, bradycardia, and hypocalcemia during first 24-48 hours after delivery. |
| Fertility Effects | No significant adverse effects on fertility reported in animal studies with amlodipine. Levamlodipine not studied specifically; class effects suggest no major impact on spermatogenesis or ovulation. Clinical data insufficient. |
| Clinical Pearls |
| CONJUPRI (levoketoconazole) is a potent CYP3A4 inhibitor; avoid coadministration with sensitive CYP3A4 substrates. Monitor liver function tests monthly due to hepatotoxicity risk. QT prolongation risk: obtain baseline ECG and monitor electrolytes. Adjust dose in hepatic impairment; contraindicated in Child-Pugh B/C. Taper dose if discontinuing after prolonged use to avoid adrenal insufficiency. |
| Patient Advice | Take exactly as prescribed; do not stop without consulting your doctor. · Report any signs of liver problems: dark urine, yellowing skin/eyes, persistent nausea. · Avoid grapefruit and grapefruit juice while taking this medication. · May cause dizziness or drowsiness; avoid driving until you know how it affects you. · Use effective contraception if of childbearing potential; this drug can harm unborn baby. · Do not take with certain other medications; provide a complete list to your doctor. |